Fallopian Tube Clear Cell Adenocarcinoma

Fallopian Tube Clear Cell Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 4
Ph III recruiting: 1
Growth YoY: —
Industry share: 8%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02713386	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	completed	Phase 1 / Phase 2	147	NRG OncologyOTHER	1	May 25, 2025	clinicaltrials
NCT01097746	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	completed	Phase 2	33	M.D. Anderson Cancer CenterOTHER	1	Oct 28, 2022